Trial Profile
A Phase II Study of PCI-32765 for Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Need Therapy and Are Older Than 65 or Have a 17p Deletion
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 14 Jun 2023 Results assessing frequency and time to detection of BTK and PLCG2 mutations in peripheral blood samples across 5 clinical trials (NCT01500733, NCT01578707, NCT01722487, NCT01744691 and NCT02264574) published in the Clinical Cancer Research
- 09 May 2023 Results of subgroup analysis (n=48; NCT02337829 and n=73; NCT01500733) assessing the role of CD49d for response to Bruton's tyrosine kinase inhibitors (BTKis) in patients with chronic lymphocytic leukemia published in the Clinical Cancer Research
- 01 Feb 2022 Results of pooled analysis of 4 studies assessing (NCT01500733, NCT01722487, NCT02264574 and NCT02048813) long-term efficacy and safety of first-line ibrutinib-based therapy in patients with CLL bearing TP53 aberrations were published in the British Journal of Haematology.